Results 181 to 190 of about 12,862 (201)

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Clinical Infectious Diseases, 2014
Evguenia S Svarovskaia, Ross Martin, Simin Xu   +2 more
exaly  

Sofosbuvir

Reactions Weekly, 2015
openaire   +2 more sources

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

Drugs, 2016
Sarah L Greig, Greig Sarah L
exaly  

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Gastroenterology, 2016
George N Ioannou, Lauren A Beste, Michael F Chang   +2 more
exaly  

Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES

Liver International, 2016
Adeel A Butt, Raymond T Chung, Kenneth E Sherman   +2 more
exaly  

The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment

Journal of Gastroenterology and Hepatology (Australia), 2020
Hossein Poustchi, Sara Majd Jabbari, Shahin Mérat   +2 more
exaly  

Prices of sofosbuvir and ledipasvir/sofosbuvir unaffordable

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical Pharmacokinetics, 2015
William T Symonds, Brian P Kearney
exaly  

Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals

Journal of Hepatology, 2020
Chen-Hua Liu, Mei-Hsuan Lee, Jou-Wei Lin   +2 more
exaly  

Daclatasvir + sofosbuvir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source